Sign Up to like & get recommendations! 1
Published in 2018 at "Journal of Clinical Apheresis"
DOI: 10.1002/jca.21679
Abstract: Extracorporeal photopheresis (ECP) is an efficient and established therapy to treat acute and chronic graft vs host disease (GVHD). Using an “off‐line” method, the first step (mononuclear cell [MNC] collection) is decisive, as long as… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Journal of Clinical Apheresis"
DOI: 10.1002/jca.21744
Abstract: Extracorporeal photopheresis (ECP) is associated with few adverse effects. We have anecdotally noted patients treated with long‐term ECP develop iron deficiency anemia (IDA). read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Journal of Clinical Apheresis"
DOI: 10.1002/jca.21870
Abstract: Stem Cell Mobilization and Collection Unit at Istituto Europeo di Oncologia (IEO; Milan, Lombardia) provides extracorporeal photopheresis (ECP) therapy to treat graft‐vs‐host disease (GvHD) using offline procedures. ECP can be administered via an integrated single… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Journal of Clinical Apheresis"
DOI: 10.1002/jca.21982
Abstract: Systemic immune‐inflammatory biomarkers (SIIBs) have not been studied in mycosis fungoides (MF) patients undergoing extracorporeal photopheresis (ECP). read more here.
Sign Up to like & get recommendations! 2
Published in 2022 at "Journal of Clinical Apheresis"
DOI: 10.1002/jca.22012
Abstract: Graft‐vs‐host disease (GVHD) is a frequent cause of morbidity and mortality in allogeneic stem cell transplants. Extracorporeal photopheresis (ECP) is one of the most accepted second‐line treatments, but technical issues of ECP in children might… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "European Journal of Cancer"
DOI: 10.1016/s0959-8049(21)00729-2
Abstract: Background: Patients with primary cutaneous lymphoma receive immunosuppressive therapy for long term disease control. Both cutaneous lymphoma and immunosuppressive treatment can contribute to the development of more severe COVID-19 complications. The real challenge during the… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Transplantation"
DOI: 10.1097/tp.0000000000001165
Abstract: Background Induction of immune tolerance by an increase in regulatory T (Treg) cells after extracorporeal photopheresis (ECP) is thought to contribute to how ECP exerts its therapeutic effect in patients with chronic graft-versus-host disease (cGvHD).… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "British Journal of Haematology"
DOI: 10.1111/bjh.14537
Abstract: Extracorporeal photopheresis (ECP) has been used for over 35 years in the treatment of erythrodermic cutaneous T‐cell lymphoma (CTCL) and over 20 years for chronic and acute graft‐versus‐host disease (GvHD) and solid organ transplant rejection.… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Dermatologic Therapy"
DOI: 10.1111/dth.15366
Abstract: Extracorporeal photopheresis (ECP) is considered a safe treatment modality. We aimed to assess blood parameters including coagulation during ECP over time. We performed a long‐term retrospective single‐center chart review (laboratory parameters) of adult patients (n… read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.16889
Abstract: Following the first investigational study on the use of extracorporeal photopheresis for the treatment of cutaneous T‐cell lymphoma published in 1983, this technology has received continued use and further recognition for additional earlier as well… read more here.